Tirzepatide produced greater average weight loss than semaglutide in SURMOUNT-5: 20.2% versus 13.7% at 72 weeks. That is a direct comparison within one randomized trial, not a comparison of headlines from unrelated studies.
The result answers a specific question about the medicines, regimens and adults studied. It does not predict what one person will lose or establish which medicine is best for every health goal.
The result at a glance
| Study medicine | Average loss |
|---|---|
| Tirzepatide | 20.2% |
| Semaglutide | 13.7% |
The difference was statistically significant. Source: the SURMOUNT-5 paper, published in 2025.
Who and what did the trial compare?
The phase 3b study randomized 751 adults without diabetes. It compared once-weekly injections for 72 weeks at the maximum tolerated trial doses: tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg. These describe the study; they are not starting-dose instructions.
It was open-label: participants and investigators knew the assigned treatment. Eli Lilly funded the trial. Those features matter when interpreting the evidence, even though treatment assignment was randomized. See the published methods and registered study, NCT05822830.
Does “47% more weight loss” mean losing 47% of your weight?
No. The two group averages differ by 6.5 percentage points: 20.2 minus 13.7. Dividing that difference by 13.7 gives approximately 47% greater relative weight loss. The denominator changes the meaning.
For a simple illustration, apply both percentages to the same hypothetical starting weight of 200 lb: 20.2% is 40.4 lb, and 13.7% is 27.4 lb. This is arithmetic to explain the headline, not a prediction or the trial’s actual average pounds lost.
What does the analysis include?
Lilly identifies these figures as the treatment-regimen estimand. An estimand is the precise treatment question an analysis aims to answer. Keep the analysis, timepoint and population together when comparing results; an on-treatment estimate from another study is not automatically interchangeable.
The sponsor describes the study population as adults with obesity, or overweight plus a weight-related condition, without diabetes. Both groups received reduced-calorie diet and physical-activity counseling. The study compared Zepbound with Wegovy. Source: Lilly’s May 11, 2025 results announcement.
What about side effects?
Digestive adverse events were the most frequent in both groups; most were mild or moderate and occurred during dose escalation. That trial description does not make a particular person’s symptoms harmless. See the paper’s safety summary.
Lilly reports that 6.1% of the tirzepatide group and 8.0% of the semaglutide group stopped treatment because of adverse events. It also states that the trial was not powered to compare safety and tolerability. Those percentages therefore should not be turned into a claim that one medicine is safer.
What does this mean for a reader?
- Supported: greater average weight reduction with tirzepatide under this head-to-head study’s conditions.
- Not answered: the best choice for your medical history, every dose or formulation, or every outcome beyond weight loss.
- Not validated: independently sold research vials carrying either compound name. They were not the products compared.
A medication decision belongs with the prescribing clinician and includes tolerability, health goals and access—not one percentage.
Continue with the tirzepatide profile, weight-loss plateau guide, or reported side effects and their evidence.